InflaRx N.V.(IFRX)Earnings, Financials & Key Ratios
IFRX•NASDAQ
$1.97
$142M mkt cap·Price updated May 6, 2026
AboutInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Show more
- Revenue$28K-83.0%
- EBITDA-$49M+7.7%
- Net Income-$44M+4.8%
- EPS (Diluted)-0.66+15.4%
- Gross Margin-26108.47%-1273.6%
- EBITDA Margin-172163.84%-443.4%
- Operating Margin-173594.03%-442.9%
- Net Margin-155584.2%-460.0%
- ROE-85.15%-51.6%
- ROIC-104.4%-77.0%
- Debt/Equity0.02+64.8%
- Interest Coverage-1297.60+41.8%
IFRX Key Insights
InflaRx N.V. (IFRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 14.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IFRX Price & Volume
InflaRx N.V. (IFRX) stock price & volume — 10-year historical chart
Loading chart...
IFRX Growth Metrics
InflaRx N.V. (IFRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-83.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.12%
Return on Capital
10 Years-51.21%
5 Years-64.42%
3 Years-68.25%
Last Year-93.99%
IFRX Recent Earnings
InflaRx N.V. (IFRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (33%)
Q2 2026Latest
Mar 19, 2026EPS
$0.17
Est $0.18
+5.6%
Revenue
$17,618
Est $27,307
-164.5%
Q4 2025
Nov 10, 2025EPS
$0.16
Est $0.16
+0.0%
Revenue
$27,910
Est $26,170
+6.7%
Q3 2025
Aug 7, 2025EPS
$0.24
Est $0.24
+0.0%
Revenue
$46,428
Est $26,000
+78.6%
Q2 2025
May 7, 2025EPS
$0.14
Est $0.18
+22.2%
Revenue
—
Est $19,380
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $0.17vs $0.18+5.6% | $17,618vs $27,307-164.5% |
| Q4 2025 | Nov 10, 2025 | $0.16vs $0.16+0.0% | $27,910vs $26,170+6.7% |
| Q3 2025 | Aug 7, 2025 | $0.24vs $0.24+0.0% | $46,428vs $26,000+78.6% |
| Q2 2025 | May 7, 2025 | $0.14vs $0.18+22.2% | —vs $19,380 |
Based on last 12 quarters of dataView full earnings history →
IFRX Peer Comparison
InflaRx N.V. (IFRX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARGX | 49.18B | 794.70 | 62.18 | 78.6% | 23.34% | 15.14% | 0.01 | |
 OMAB | 5.15B | 106.74 | 16.70 | 5.91% | 33.46% | 50.64% | 8.26% | 1.19 |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 VKTX | 3.63B | 31.31 | -9.82 | -71.31% | 0.00 | |||
 ALXO | 103.4M | 1.93 | -0.75 | -241.09% | 0.15 | |||
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 CABA | 424.39M | 4.15 | -2.53 | -121.73% | 0.24 | |||
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 |
Compare IFRX vs Peers
InflaRx N.V. (IFRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IFRX Income Statement
InflaRx N.V. (IFRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 231K | 0 | 0 | 0 | 0 | 0 | 63.09K | 165.79K | 28.17K |
| Revenue Growth % | - | -100% | - | - | - | - | - | 162.79% | -83.01% |
| Cost of Goods Sold | 66.69K | 179.57K | 742.25K | 812.47K | 791.26K | 627.01K | 532.26K | 3.32M | 7.38M |
| COGS % of Revenue | 28.87% | - | - | - | - | - | 843.67% | 2000.76% | 26208.47% |
| Gross Profit | 164.31K▲ 0% | -179.57K▼ 209.3% | -742.25K▼ 313.3% | -812.47K▼ 9.5% | -791.26K▲ 2.6% | -627.01K▲ 20.8% | -469.17K▲ 25.2% | -3.15M▼ 571.7% | -7.36M▼ 133.4% |
| Gross Margin % | 71.13% | - | - | - | - | - | -743.67% | -1900.76% | -26108.47% |
| Gross Profit Growth % | 560.79% | -209.29% | -313.35% | -9.46% | 2.61% | 20.76% | 25.17% | -571.66% | -133.42% |
| Operating Expenses | 19.45M | 37.52M | 63.15M | 38.12M | 55.57M | 54.44M | 44.44M | 49.86M | 41.55M |
| OpEx % of Revenue | 8418.18% | - | - | - | - | - | 70438.46% | 30072.93% | 147485.56% |
| Selling, General & Admin | 5.14M | 12.79M | 13.43M | 9.02M | 13.51M | 15.07M | 16.12M | 19.33M | 16.85M |
| SG&A % of Revenue | 2224.24% | - | - | - | - | - | 25554.61% | 11656.71% | 59792.89% |
| Research & Development | 14.41M | 25.03M | 49.72M | 29.1M | 42.05M | 39.37M | 41.02M | 35.36M | 24.71M |
| R&D % of Revenue | 6240.26% | - | - | - | - | - | 65025.81% | 21330.67% | 87692.67% |
| Other Operating Expenses | -107K | -299K | 0 | 0 | 0 | 0 | -12.71M | -4.83M | 0 |
| Operating Income | -19.45M▲ 0% | -37.52M▼ 92.9% | -63.89M▼ 70.3% | -38.93M▲ 39.1% | -56.36M▼ 44.8% | -55.07M▲ 2.3% | -44.91M▲ 18.4% | -53.01M▼ 18.0% | -48.91M▲ 7.7% |
| Operating Margin % | -8417.75% | - | - | - | - | - | -71182.13% | -31973.69% | -173594.03% |
| Operating Income Growth % | -182.18% | -92.93% | -70.3% | 39.06% | -44.77% | 2.3% | 18.45% | -18.04% | 7.74% |
| EBITDA | -19.38M | -37.34M | -63.15M | -38.12M | -55.57M | -54.44M | -44.34M | -52.52M | -48.5M |
| EBITDA Margin % | -8388.88% | - | - | - | - | - | -70282.17% | -31681.08% | -172163.84% |
| EBITDA Growth % | -182.67% | -92.67% | -69.13% | 39.64% | -45.78% | 2.03% | 18.55% | -18.46% | 7.65% |
| D&A (Non-Cash Add-back) | 66.69K | 179.57K | 742.25K | 812.47K | 791.26K | 627.01K | 567.78K | 485.11K | 402.93K |
| EBIT | -22.01M | 0 | -59.58M | -38.71M | -53.9M | -30.94M | -42.63M | -46.04M | -48.91M |
| Net Interest Income | -2.1M | 0 | 2.82M | 861.7K | 84.62K | 563.43K | 3.77M | 3.18M | 1.73M |
| Interest Income | 130K | 2.18M | 2.84M | 887.7K | 109.39K | 608.68K | 3.8M | 3.2M | 1.77M |
| Interest Expense | 2.23M | 0 | 22.2K | 26K | 24.77K | 45.25K | 35.63K | 20.66K | 37.69K |
| Other Income/Expense | -4.79M | 7.7M | 4.28M | 191.21K | 2.43M | 24.08M | 2.24M | 6.95M | 5.06M |
| Pretax Income | -24.24M▲ 0% | -29.81M▼ 23.0% | -59.61M▼ 99.9% | -38.74M▲ 35.0% | -53.93M▼ 39.2% | -30.99M▲ 42.5% | -42.67M▼ 37.7% | -46.06M▼ 7.9% | -43.84M▲ 4.8% |
| Pretax Margin % | -10492.64% | - | - | - | - | - | -67630.69% | -27781.81% | -155626.07% |
| Income Tax | 0 | 7.7M | 0 | 0 | 0 | 0 | 0 | 5.22K | -11.8K |
| Effective Tax Rate % | 0% | -25.83% | 0% | 0% | 0% | 0% | 0% | -0.01% | 0.03% |
| Net Income | -24.24M▲ 0% | -29.82M▼ 23.0% | -59.61M▼ 99.9% | -38.74M▲ 35.0% | -53.93M▼ 39.2% | -30.99M▲ 42.5% | -42.67M▼ 37.7% | -46.06M▼ 8.0% | -43.83M▲ 4.8% |
| Net Margin % | -10492.64% | - | - | - | - | - | -67630.69% | -27784.96% | -155584.2% |
| Net Income Growth % | -171.15% | -23.01% | -99.92% | 35.01% | -39.22% | 42.55% | -37.69% | -7.96% | 4.84% |
| Net Income (Continuing) | -24.24M | -29.82M | -59.61M | -38.74M | -53.93M | -30.99M | -42.67M | -46.06M | -43.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.03▲ 0% | -1.19▼ 15.5% | -1.91▼ 60.5% | -1.26▲ 34.0% | -1.10▲ 12.7% | -0.61▲ 44.5% | -0.78▼ 27.9% | -0.78▲ 0.0% | -0.66▲ 15.4% |
| EPS Growth % | -171.05% | -15.53% | -60.5% | 34.03% | 12.7% | 44.55% | -27.87% | 0% | 15.38% |
| EPS (Basic) | -1.03 | -1.19 | -1.91 | -1.26 | -1.10 | -0.61 | -0.78 | -0.78 | -0.66 |
| Diluted Shares Outstanding | 23.61M | 25.1M | 26M | 27.06M | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
| Basic Shares Outstanding | 23.61M | 25.09M | 26M | 27.06M | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IFRX Balance Sheet
InflaRx N.V. (IFRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 123.98M | 158.16M | 118.99M | 86.28M | 95.68M | 97.41M | 109.47M | 71.66M | 53.61M |
| Cash & Short-Term Investments | 123.28M | 156.57M | 115.49M | 81.13M | 83.41M | 81.81M | 12.77M | 18.38M | 46.44M |
| Cash Only | 123.28M | 55.39M | 33.13M | 25.97M | 26.25M | 16.27M | 12.77M | 18.38M | 16.02M |
| Short-Term Investments | 0 | 101.18M | 82.35M | 55.16M | 57.16M | 65.54M | 0 | 0 | 30.42M |
| Accounts Receivable | 120K | 0 | 0 | 0 | 1.28M | 1.43M | 0 | 0 | 1.43M |
| Days Sales Outstanding | 189.61 | - | - | - | - | - | - | - | 18.5K |
| Inventory | 504K | 0 | 0 | 0 | 0 | 0 | 11.37M | 6.9M | 0 |
| Days Inventory Outstanding | 2.76K | - | - | - | - | - | 7.8K | 759 | - |
| Other Current Assets | 73K | 541.42K | 1.33M | 3.86M | 0 | 2.55M | 85.06M | 46.03M | 5.75M |
| Total Non-Current Assets | 234K | 1.05M | 2.59M | 1.93M | 29.46M | 4.99M | 10.74M | 4.36M | 1.58M |
| Property, Plant & Equipment | 173K | 625K | 1.41M | 954.96K | 1.68M | 1.64M | 1.36M | 1.01M | 1.15M |
| Fixed Asset Turnover | 1.34x | - | - | - | - | - | 0.05x | 0.16x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 41K | 223K | 452.4K | 350.18K | 235.22K | 138.91K | 42.84K | 7.26K | 42.24K |
| Long-Term Investments | 20K | 207K | 272.61K | 272.27K | 27.21M | 2.9M | 9.05M | 3.09M | 237.27K |
| Other Non-Current Assets | 193K | 0 | 452.22K | 353.52K | 336.57K | 308.07K | 283.25K | 247.75K | 151.13K |
| Total Assets | 124.21M▲ 0% | 159.21M▲ 28.2% | 121.58M▼ 23.6% | 88.22M▼ 27.4% | 125.14M▲ 41.9% | 102.4M▼ 18.2% | 120.21M▲ 17.4% | 76.02M▼ 36.8% | 55.19M▼ 27.4% |
| Asset Turnover | 0.00x | - | - | - | - | - | 0.00x | 0.00x | 0.00x |
| Asset Growth % | 320.8% | 28.18% | -23.64% | -27.44% | 41.86% | -18.17% | 17.39% | -36.76% | -27.4% |
| Total Current Liabilities | 4.77M | 7.76M | 14.06M | 10.1M | 18.76M | 13.03M | 16.84M | 14.17M | 12.98M |
| Accounts Payable | 4.47M | 6.66M | 12.41M | 1.74M | 1.69M | 4.99M | 5.1M | 3.41M | 5.4M |
| Days Payables Outstanding | 24.46K | 13.53K | 6.1K | 782.25 | 777.29 | 2.9K | 3.5K | 375.57 | 266.79 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 256.83K |
| Deferred Revenue (Current) | 15K | 0 | 0 | 0 | 8.3M | 6.21M | 0 | 0 | 0 |
| Other Current Liabilities | 298K | 1.1M | 1.13M | 132.73K | 1.52M | -1.96M | 2.89M | 301.54K | 6.16M |
| Current Ratio | 26.01x | 20.39x | 8.46x | 8.54x | 5.10x | 7.48x | 6.50x | 5.06x | 4.13x |
| Quick Ratio | 25.90x | 20.39x | 8.46x | 8.54x | 5.10x | 7.48x | 5.82x | 4.57x | 4.13x |
| Cash Conversion Cycle | -21.51K | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 17K | 67K | 369.76K | 253.85K | 1.1M | 1.02M | 782.59K | 435.94K | 677.56K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 330.75K | 220.53K | 1.07M | 987.31K | 745.72K | 399.07K | 640.7K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2K | 56K | 39.01K | 33.32K | 35.02K | 36.88K | 36.88K | 36.88K | 36.86K |
| Total Liabilities | 4.78M | 7.82M | 14.43M | 10.35M | 19.86M | 14.05M | 17.63M | 14.6M | 13.65M |
| Total Debt | 0 | 0 | 845.95K | 559.04K | 1.43M | 1.36M | 1.12M | 805.09K | 897.53K |
| Net Debt | -123.28M | -55.39M | -32.29M | -25.41M | -24.82M | -14.91M | -11.65M | -17.57M | -15.12M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x | 0.01x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -9.87x | - | -2683.80x | -1488.88x | -2176.29x | -683.76x | -1196.58x | -2228.93x | -1297.60x |
| Total Equity | 119.43M▲ 0% | 151.39M▲ 26.8% | 107.15M▼ 29.2% | 77.86M▼ 27.3% | 105.28M▲ 35.2% | 88.35M▼ 16.1% | 102.58M▲ 16.1% | 61.42M▼ 40.1% | 41.54M▼ 32.4% |
| Equity Growth % | 564.9% | 26.76% | -29.23% | -27.33% | 35.21% | -16.08% | 16.11% | -40.13% | -32.36% |
| Book Value per Share | 5.06 | 6.03 | 4.12 | 2.88 | 2.53 | 2.00 | 1.87 | 1.04 | 0.62 |
| Total Shareholders' Equity | 119.43M | 151.39M | 107.15M | 77.86M | 105.28M | 88.35M | 102.58M | 61.42M | 41.54M |
| Common Stock | 2.86M | 3.12M | 3.13M | 3.39M | 5.3M | 5.36M | 7.07M | 7.12M | 8.67M |
| Retained Earnings | -51.29M | -81.11M | -134.36M | -168.35M | -213.98M | -243.46M | -286.13M | -332.19M | -377.67M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 167.86M | 18.31M | 25.14M | 22.53M | 30.59M | 36.64M | 47.43M | 51.56M | 48.54M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IFRX Cash Flow Statement
InflaRx N.V. (IFRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.15M | -23.71M | -43.2M | -36.53M | -39.94M | -33.74M | -37.81M | -48.56M | -33.92M |
| Operating CF Margin % | -5260.61% | - | - | - | - | - | -59935.91% | -29288.25% | -120400.97% |
| Operating CF Growth % | -143.38% | -95.13% | -82.21% | 15.45% | -9.33% | 15.51% | -12.06% | -28.41% | 30.14% |
| Net Income | -24.24M | -29.82M | -53.25M | -33.98M | -45.63M | -29.48M | -42.67M | -46.06M | -43.83M |
| Depreciation & Amortization | 71K | 174K | 663.17K | 712.71K | 669.43K | 596.6K | 567.78K | 485.11K | 402.93K |
| Stock-Based Compensation | 4.55M | 12.09M | 6.83M | 1.12M | 4.33M | 6.04M | 3.41M | 4.07M | 0 |
| Deferred Taxes | 66K | -1.88M | 0 | 927.84K | 1.16M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.82M | -6.11M | 4.89M | 44.25K | -2M | -1.13M | -131.29K | -4.76M | 4.84M |
| Working Capital Changes | 2.58M | 1.83M | -2.34M | -5.35M | 1.54M | -9.77M | 1M | -2.28M | 4.66M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.12M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -11.37M | 4.47M | 6.63M |
| Change in Payables | 3.09M | 2.19M | 0 | -3.87M | 316.11K | -3.52M | 0 | 0 | -5.76M |
| Cash from Investing | -167K | -99.45M | 20.34M | 21.36M | -25.95M | 19.36M | -17.7M | 52.36M | 3.11M |
| Capital Expenditures | -149K | -806K | -594.89K | -94.19K | -37.78K | -162.39K | -81.1K | -46.87K | -111.13K |
| CapEx % of Revenue | 64.5% | - | - | - | - | - | 128.55% | 28.27% | 394.44% |
| Acquisitions | 0 | 806K | 0 | 94.19K | 37.78K | -19.52M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 1K | -808K | 20.94M | -94.19K | -37.78K | 19.52M | 0 | 1 | -3 |
| Cash from Financing | 108.8M | 49.64M | -294.34K | 9.17M | 61.58M | 1.94M | 52.99M | 386.45K | 32M |
| Debt Issued (Net) | 0 | 0 | -296.02K | -366.16K | -360.64K | -364.43K | -373.98K | -388.11K | -357.58K |
| Equity Issued (Net) | 117.92M | 52.99M | 0 | 9.77M | 65.14M | 2.35M | 56.48M | 1.1M | 32.35M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -9.11M | -3.35M | 1.68K | -232.9K | -3.2M | -47.73K | -3.12M | -323.73K | 14.11K |
| Net Change in Cash | 94.17M▲ 0% | -67.9M▼ 172.1% | -22.25M▲ 67.2% | -7.16M▲ 67.8% | 281.31K▲ 103.9% | -9.98M▼ 3649.3% | -3.5M▲ 65.0% | 5.61M▲ 260.3% | -179.66K▼ 103.2% |
| Free Cash Flow | -12.3M▲ 0% | -24.52M▼ 99.3% | -43.8M▼ 78.6% | -36.62M▲ 16.4% | -39.97M▼ 9.2% | -33.91M▲ 15.2% | -37.89M▼ 11.8% | -48.6M▼ 28.3% | -34.03M▲ 30.0% |
| FCF Margin % | -5325.11% | - | - | - | - | - | -60064.46% | -29316.52% | -120795.42% |
| FCF Growth % | -143.78% | -99.32% | -78.64% | 16.39% | -9.15% | 15.18% | -11.76% | -28.26% | 29.98% |
| FCF per Share | -0.52 | -0.98 | -1.68 | -1.35 | -0.96 | -0.77 | -0.69 | -0.82 | -0.51 |
| FCF Conversion (FCF/Net Income) | 0.50x | 0.80x | 0.72x | 0.94x | 0.74x | 1.09x | 0.89x | 1.05x | 0.77x |
| Interest Paid | 0 | 0 | 20.9K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IFRX Key Ratios
InflaRx N.V. (IFRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -51.71% | -22.02% | -46.11% | -41.88% | -58.9% | -32.01% | -44.69% | -56.18% | -85.15% |
| Return on Invested Capital (ROIC) | - | - | -61.07% | -56.09% | -45.87% | -63.6% | -53.67% | -40.98% | -59% | -104.4% |
| Gross Margin | - | 71.13% | - | - | - | - | - | -743.67% | -1900.76% | -26108.47% |
| Net Margin | - | -10492.64% | - | - | - | - | - | -67630.69% | -27784.96% | -155584.2% |
| Debt / Equity | - | - | - | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x | 0.01x | 0.02x |
| Interest Coverage | -3.87x | -9.87x | - | -2683.80x | -1488.88x | -2176.29x | -683.76x | -1196.58x | -2228.93x | -1297.60x |
| FCF Conversion | 0.56x | 0.50x | 0.80x | 0.72x | 0.94x | 0.74x | 1.09x | 0.89x | 1.05x | 0.77x |
| Revenue Growth | - | - | -100% | - | - | - | - | - | 162.79% | -83.01% |
IFRX Frequently Asked Questions
InflaRx N.V. (IFRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
InflaRx N.V. (IFRX) reported $0.0M in revenue for fiscal year 2025.
InflaRx N.V. (IFRX) saw revenue decline by 83.0% over the past year.
InflaRx N.V. (IFRX) reported a net loss of $43.8M for fiscal year 2025.
Dividend & Returns
InflaRx N.V. (IFRX) has a return on equity (ROE) of -85.1%. Negative ROE indicates the company is unprofitable.
InflaRx N.V. (IFRX) had negative free cash flow of $35.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More IFRX
InflaRx N.V. (IFRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates